Literature DB >> 10739171

Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease.

A J Makoff1, J M Graham, M J Arranz, J Forsyth, T Li, K J Aitchison, S Shaikh, R A Grünewald.   

Abstract

Some patients with idiopathic Parkinson's disease experience hallucinations as a result of treatment with levodopa and dopamine agonists. There is evidence for some heterogeneity in these hallucinating patients based on duration of Parkinson's disease at onset of hallucinations. We compared the frequency of polymorphisms in the dopamine D2 and D3 receptor genes between patients with drug-induced hallucinations and non-hallucinating patients. Two polymorphisms close to DRD2 and one in DRD3 were studied. No association was found with the whole group of hallucinating patients and their controls. However, an association was found with late-onset hallucinations and the C allele of the TaqIA polymorphism, 10.5 kb 3' to DRD2. This polymorphism may be in linkage disequilibrium with a mutation in DRD2 or a nearby gene that predisposes to drug-induced hallucinations which occur later in the course of idiopathic Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10739171     DOI: 10.1097/00008571-200002000-00006

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  20 in total

Review 1.  An update expert opinion on management and research strategies in Parkinson's disease psychosis.

Authors:  Jennifer G Goldman; Christina L Vaughan; Christopher G Goetz
Journal:  Expert Opin Pharmacother       Date:  2011-06-02       Impact factor: 3.889

Review 2.  Receptor pharmacogenetics: relevance to CNS syndromes.

Authors:  Sanober Shaikh; Robert W Kerwin
Journal:  Br J Clin Pharmacol       Date:  2002-10       Impact factor: 4.335

Review 3.  The genetic basis of Parkinson's disease.

Authors:  T Foltynie; S Sawcer; C Brayne; R A Barker
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-10       Impact factor: 10.154

Review 4.  Psychotic symptoms in Parkinson's disease. From description to etiology.

Authors:  Spiridon Papapetropoulos; D C Mash
Journal:  J Neurol       Date:  2005-07       Impact factor: 4.849

5.  Association of dopamine receptor gene polymorphisms with the clinical course of Wilson disease.

Authors:  T Litwin; G Gromadzka; J Samochowiec; A Grzywacz; A Członkowski; A Członkowska
Journal:  JIMD Rep       Date:  2012-07-06

Review 6.  Neuropsychiatric aspects of Parkinson's disease: recent advances.

Authors:  Laura Marsh; Ariel Berk
Journal:  Curr Psychiatry Rep       Date:  2003-05       Impact factor: 5.285

Review 7.  [Parkinson's disease and psychoses].

Authors:  Jacopo Vittoriano Bizzarri; Giancarlo Giupponi; Ignazio Maniscalco; Patrizia Schroffenegger; Andreas Conca; Hans Peter Kapfhammer
Journal:  Neuropsychiatr       Date:  2015-01-14

Review 8.  Genetics and Treatment Response in Parkinson's Disease: An Update on Pharmacogenetic Studies.

Authors:  Cristina Politi; Cinzia Ciccacci; Giuseppe Novelli; Paola Borgiani
Journal:  Neuromolecular Med       Date:  2018-01-05       Impact factor: 3.843

9.  Reward processing abnormalities in Parkinson's disease.

Authors:  Dimitrios Kapogiannis; Eric Mooshagian; Paul Campion; Jordan Grafman; Trelawny J Zimmermann; Kelsey C Ladt; Eric M Wassermann
Journal:  Mov Disord       Date:  2011-04-29       Impact factor: 10.338

10.  Polymorphisms of dopamine receptor genes and risk of visual hallucinations in Parkinson's patients.

Authors:  M Ferrari; C Comi; F Marino; L Magistrelli; F De Marchi; R Cantello; G Riboldazzi; G Bono; M Cosentino
Journal:  Eur J Clin Pharmacol       Date:  2016-08-06       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.